The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
BUSINESS
Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
Sumitomo Dainippon Pharma said on November 27 that it has reached a settlement with all 16 generic firms over patent infringement lawsuits in the US regarding its antipsychotic agent Latuda (lurasidone). Sumitomo Dainippon filed lawsuits jointly with its US unit…
To read the full story
Related Article
- Latuda Challenged Again over Use Patent Validity in US: Sumitomo Dainippon
June 23, 2020
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
BUSINESS
- GSK Applauds Japan’s Plan to Include Shingles Vaccines in NIP
December 19, 2024
- Sumitomo Plots 350 Billion Yen Cell Therapy Biz in Late 2030s
December 18, 2024
- Sumitomo Group to Launch Regenerative/Cell Therapy Joint Venture
December 18, 2024
- Chugai Touts 9 Late-Stage Oncology Assets for 23 Indications, Hails Deregulations
December 18, 2024
- Daiichi Sankyo Puts Up 600 Billion Yen to Bolster ADC Supply Regime
December 18, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…